Emergent BioSolutions | EBS - Pre Tax Profit


Emergent BioSolutions reported $-130.8M in Pre-Tax Profit for its fiscal quarter ending in March of 2023.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Akebia Therapeutics USD -11.24M 12.39M Dec/2025
ALKERMES USD -61.93M 122.3M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amarin USD -852K 7.26M Dec/2025
ANI Pharmaceuticals USD 31.48M 18.04M Dec/2025
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Exelixis USD 267.69M 15M Mar/2026
Glaxosmithkline GBP 2.46B 569M Sep/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Ironwood Pharmaceuticals USD 68.02M 30.2M Sep/2025
Lexicon Pharmaceuticals USD -12.77M 16.02M Sep/2025
Lonza CHF 624M 197M Dec/2024
Merck USD 3.42B 3.32B Dec/2025
Moderna USD -799M 612M Dec/2025
Myriad Genetics USD 4.6M 3.4M Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Pacira USD 571K 8.95M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
United Therapeutics USD 444M 6M Dec/2025
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024
Xoma USD 15.98M 24.58M Jun/2024